SONN vs. SNSE, PPBT, MEIP, VINC, NRBO, LUMO, SYBX, KALA, VBIV, and GLYC
Should you be buying Sonnet BioTherapeutics stock or one of its competitors? The main competitors of Sonnet BioTherapeutics include Sensei Biotherapeutics (SNSE), Purple Biotech (PPBT), MEI Pharma (MEIP), Vincerx Pharma (VINC), NeuroBo Pharmaceuticals (NRBO), Lumos Pharma (LUMO), Synlogic (SYBX), KALA BIO (KALA), VBI Vaccines (VBIV), and GlycoMimetics (GLYC). These companies are all part of the "pharmaceutical preparations" industry.
Sensei Biotherapeutics (NASDAQ:SNSE) and Sonnet BioTherapeutics (NASDAQ:SONN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability, community ranking and analyst recommendations.
Sensei Biotherapeutics has a beta of 0.14, meaning that its stock price is 86% less volatile than the S&P 500. Comparatively, Sonnet BioTherapeutics has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500.
Sensei Biotherapeutics has a net margin of 0.00% compared to Sensei Biotherapeutics' net margin of -11,187.19%. Sonnet BioTherapeutics' return on equity of -46.67% beat Sensei Biotherapeutics' return on equity.
Sensei Biotherapeutics received 7 more outperform votes than Sonnet BioTherapeutics when rated by MarketBeat users. However, 81.82% of users gave Sonnet BioTherapeutics an outperform vote while only 78.13% of users gave Sensei Biotherapeutics an outperform vote.
In the previous week, Sonnet BioTherapeutics had 4 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 8 mentions for Sonnet BioTherapeutics and 4 mentions for Sensei Biotherapeutics. Sensei Biotherapeutics' average media sentiment score of 0.64 beat Sonnet BioTherapeutics' score of 0.11 indicating that Sonnet BioTherapeutics is being referred to more favorably in the news media.
Sonnet BioTherapeutics has higher revenue and earnings than Sensei Biotherapeutics.
10.5% of Sensei Biotherapeutics shares are owned by institutional investors. Comparatively, 9.5% of Sonnet BioTherapeutics shares are owned by institutional investors. 25.5% of Sensei Biotherapeutics shares are owned by insiders. Comparatively, 2.0% of Sonnet BioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Sensei Biotherapeutics currently has a consensus target price of $4.50, indicating a potential upside of 508.44%. Sonnet BioTherapeutics has a consensus target price of $30.00, indicating a potential upside of 1,810.83%. Given Sensei Biotherapeutics' higher probable upside, analysts clearly believe Sonnet BioTherapeutics is more favorable than Sensei Biotherapeutics.
Summary
Sonnet BioTherapeutics beats Sensei Biotherapeutics on 7 of the 13 factors compared between the two stocks.
Get Sonnet BioTherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SONN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SONN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sonnet BioTherapeutics Competitors List
Related Companies and Tools
